Skip to main content
Resources

Patient education

Explore resources to support your patients’ journey in considering, preparing for, and living with Enterra™ Therapy.

Understanding gastroparesis

Challenge of Gastroparesis Brochure cover

The challenge of gastroparesis brochure

File type: PDF

Patient brochure that provides an overview of gastroparesis, as well as possible treatment options.

Patient Symptom Tracker thumbnail

Patient symptom tracker

File type: PDF

A log to help your patients record the severity and frequency of their gastroparesis symptoms.

Nausea Vomiting Diary thumbnail

Symptom diary

File type: PDF

A tool to help your patients track the number of hours they experience nausea and vomiting each day.

Nutrition recommendations

File type: PDF

A patient resource for nutrition tips and recommendations.

Introduction to Enterra Therapy

A 3-minute video explaining gastroparesis and Enterra Therapy to patients.

Patient stories

Mary's story

See how Enterra Therapy positively impacted her gastroparesis symptoms.

Cindy's story

See the difference that Enterra Therapy has made in Cindy’s daily life.

Sadila’s story

File type: PDF

Read about how Enterra Therapy helped Sadila get her life back on track.

Geoff Patient Story PDF thumbnail

Geoff’s story

File type: PDF

Read about Geoff’s journey with gastroparesis and with Enterra Therapy.

Jonna’s story

File type: PDF

Read about Jonna’s experience with gastroparesis and how she’s determined to make a positive impact for others.

Paul’s story

File type: PDF

Read about Paul’s 20-year experience with Enterra Therapy and the difference it’s made in his life.

MKT-D-0006, Rev F

IMPORTANT SAFETY INFORMATION

Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.

HUMANITARIAN DEVICE

Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?